new retatrutide weight-loss drug showing stronger results than current options Retatrutide UK 2026: Phase 3

CJC-1131, a long acting GLP-1 analog, safely normalizes post-prandial glucose excursion and fasting glycemia in type 2 diabetes mellitus [abstract]

However, the 12mg maintenance dose still requires multiple draws or a 1mL+ syringe

Are overweight or have obesity, especially if they also have diabetes or other health risks (Trulicity and Mounjaro are not indicated for the treatment of overweight or obesity, however)

"The most important one is just the weight loss and therefore less stress on the spine

Which one has more side effects

This compound has gained significant attention within the scientific community for its unique receptor activity profile and ongoing research interest in controlled laboratory settings